Tenax Research Development vs Operating Income Analysis

TENX Stock  USD 6.01  0.07  1.18%   
Tenax Therapeutics financial indicator trend analysis is much more than just breaking down Tenax Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tenax Therapeutics is a good investment. Please check the relationship between Tenax Therapeutics Research Development and its Operating Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Research Development vs Operating Income

Research Development vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tenax Therapeutics Research Development account and Operating Income. At this time, the significance of the direction appears to have pay attention.
The correlation between Tenax Therapeutics' Research Development and Operating Income is -0.74. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Operating Income in the same time period over historical financial statements of Tenax Therapeutics, assuming nothing else is changed. The correlation between historical values of Tenax Therapeutics' Research Development and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Tenax Therapeutics are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Research Development i.e., Tenax Therapeutics' Research Development and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.74
Relationship DirectionNegative 
Relationship StrengthWeak

Research Development

Operating Income

Operating Income is the amount of profit realized from Tenax Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Tenax Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most indicators from Tenax Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tenax Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.At this time, Tenax Therapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 0.49 in 2024, whereas Selling General Administrative is likely to drop slightly above 4.9 M in 2024.
 2021 2022 2023 2024 (projected)
Other Operating Expenses32.7M11.1M8.2M8.4M
Depreciation And Amortization109.0K113.3K7.6K7.2K

Tenax Therapeutics fundamental ratios Correlations

-0.220.190.131.0-0.17-0.990.27-0.140.990.761.00.340.91-0.130.110.891.00.26-0.19-0.19-0.2-0.53-0.390.02-0.31
-0.22-0.04-0.04-0.260.720.280.33-0.03-0.23-0.13-0.25-0.20.17-0.17-0.430.16-0.25-0.22-0.1-0.10.730.090.35-0.160.56
0.19-0.040.830.16-0.2-0.140.05-0.130.140.330.16-0.070.11-0.170.010.380.16-0.17-0.18-0.18-0.18-0.06-0.350.05-0.06
0.13-0.040.830.11-0.29-0.1-0.190.360.10.160.10.30.010.310.250.340.11-0.03-0.33-0.33-0.230.02-0.27-0.160.02
1.0-0.260.160.11-0.2-1.00.25-0.140.990.761.00.340.9-0.120.130.871.00.27-0.18-0.18-0.23-0.53-0.40.03-0.33
-0.170.72-0.2-0.29-0.20.20.46-0.31-0.17-0.07-0.2-0.260.17-0.47-0.560.11-0.2-0.220.140.140.980.030.520.080.6
-0.990.28-0.14-0.1-1.00.2-0.220.1-1.0-0.74-1.0-0.36-0.880.09-0.16-0.85-1.0-0.280.190.190.240.520.39-0.010.34
0.270.330.05-0.190.250.46-0.22-0.530.240.280.23-0.190.47-0.62-0.930.390.23-0.270.60.60.37-0.180.270.670.45
-0.14-0.03-0.130.36-0.14-0.310.1-0.53-0.11-0.38-0.120.74-0.240.820.52-0.11-0.110.05-0.31-0.3-0.220.23-0.05-0.42-0.19
0.99-0.230.140.10.99-0.17-1.00.24-0.110.751.00.350.91-0.10.130.871.00.27-0.19-0.19-0.2-0.53-0.370.01-0.32
0.76-0.130.330.160.76-0.07-0.740.28-0.380.750.75-0.180.71-0.270.00.720.750.16-0.12-0.12-0.14-0.66-0.370.17-0.19
1.0-0.250.160.11.0-0.2-1.00.23-0.121.00.750.340.9-0.120.140.871.00.26-0.21-0.21-0.23-0.53-0.410.0-0.34
0.34-0.2-0.070.30.34-0.26-0.36-0.190.740.35-0.180.340.20.570.340.290.350.21-0.18-0.18-0.20.05-0.14-0.23-0.28
0.910.170.110.010.90.17-0.880.47-0.240.910.710.90.2-0.31-0.140.940.90.12-0.18-0.180.14-0.5-0.250.0-0.06
-0.13-0.17-0.170.31-0.12-0.470.09-0.620.82-0.1-0.27-0.120.57-0.310.62-0.19-0.10.51-0.23-0.22-0.390.150.08-0.31-0.26
0.11-0.430.010.250.13-0.56-0.16-0.930.520.130.00.140.34-0.140.62-0.070.150.37-0.68-0.68-0.48-0.02-0.42-0.67-0.58
0.890.160.380.340.870.11-0.850.39-0.110.870.720.870.290.94-0.19-0.070.870.13-0.27-0.270.09-0.46-0.29-0.04-0.02
1.0-0.250.160.111.0-0.2-1.00.23-0.111.00.751.00.350.9-0.10.150.870.27-0.21-0.21-0.23-0.52-0.41-0.01-0.34
0.26-0.22-0.17-0.030.27-0.22-0.28-0.270.050.270.160.260.210.120.510.370.130.270.040.03-0.23-0.160.270.05-0.36
-0.19-0.1-0.18-0.33-0.180.140.190.6-0.31-0.19-0.12-0.21-0.18-0.18-0.23-0.68-0.27-0.210.041.00.030.060.630.950.06
-0.19-0.1-0.18-0.33-0.180.140.190.6-0.3-0.19-0.12-0.21-0.18-0.18-0.22-0.68-0.27-0.210.031.00.030.060.620.950.06
-0.20.73-0.18-0.23-0.230.980.240.37-0.22-0.2-0.14-0.23-0.20.14-0.39-0.480.09-0.23-0.230.030.030.150.48-0.040.61
-0.530.09-0.060.02-0.530.030.52-0.180.23-0.53-0.66-0.530.05-0.50.15-0.02-0.46-0.52-0.160.060.060.150.22-0.10.14
-0.390.35-0.35-0.27-0.40.520.390.27-0.05-0.37-0.37-0.41-0.14-0.250.08-0.42-0.29-0.410.270.630.620.480.220.480.31
0.02-0.160.05-0.160.030.08-0.010.67-0.420.010.170.0-0.230.0-0.31-0.67-0.04-0.010.050.950.95-0.04-0.10.480.0
-0.310.56-0.060.02-0.330.60.340.45-0.19-0.32-0.19-0.34-0.28-0.06-0.26-0.58-0.02-0.34-0.360.060.060.610.140.310.0
Click cells to compare fundamentals

Tenax Therapeutics Account Relationship Matchups

Tenax Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets6.4M6.9M6.0M3.4M11.7M15.5M
Other Current Liab760.0K1.2M597.1K655.7K1.0M790.7K
Total Current Liabilities2.5M2.1M1.6M1.8M3.6M3.8M
Total Stockholder Equity3.8M4.6M4.2M1.5M8.1M12.7M
Property Plant And Equipment Net8.5K176.0K64.8K294.8K186.7K0.0
Net Debt(4.7M)(5.9M)(5.3M)(1.3M)(9.3M)(9.8M)
Retained Earnings(236.2M)(246.0M)(278.5M)(289.5M)(297.3M)(282.4M)
Accounts Payable1.7M757.9K859.6K448.4K2.1M2.2M
Cash4.9M6.3M5.6M2.1M9.8M9.6M
Non Current Assets Total184.4K73.2K303.2K196.2K1.1K1.1K
Cash And Short Term Investments5.4M6.7M5.6M2.1M9.8M10.0M
Common Stock Shares Outstanding309.8K6.5K12.9K18.4K248.4K260.9K
Liabilities And Stockholders Equity6.4M6.9M6.0M3.4M11.7M15.5M
Non Current Liabilities Total749.8K60.4K124.2K183.6K64.2K0.0
Other Current Assets781.0K82.6K105.1K1.1M1.9M2.0M
Other Stockholder Equity239.9M250.6M282.7M291.0M305.4M320.6M
Total Liab2.6M2.2M1.7M1.9M3.6M2.8M
Total Current Assets6.2M6.8M5.7M3.2M11.7M10.5M
Common Stock674.01.3K2.5K4.6K30.028.5
Common Stock Total Equity141.0379.0674.01.3K1.1K1.1K
Property Plant And Equipment Gross8.5K176.0K6.0K294.8K186.7K0.0
Accumulated Other Comprehensive Income(16.2K)516.0458.0(70.0)(63.0)(66.15)
Property Plant Equipment8.5K6.6K64.8K294.8K265.3K172.3K
Net Tangible Assets11.8M3.8M4.6M4.2M3.8M3.6M
Retained Earnings Total Equity(213.5M)(227.8M)(236.2M)(246.0M)(221.4M)(232.5M)
Capital Surpluse222.4M239.6M239.9M250.6M288.2M226.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.